He presented results of the international study today at the American Society of Hematology???s annual meeting in Atlanta. ???It???s unusual to see this kind of response in patients so far along in the course of their disease, especially since they previously did not response to other alkylators and were relapsed from rituximab,??? said Friedberg, associate director of lymphoma clinical research a